Aprea Therapeutics (NASDAQ:APRE) Posts Earnings Results, Misses Expectations By $0.36 EPS

Aprea Therapeutics (NASDAQ:APRE) announced its quarterly earnings data on Wednesday. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.36), Zacks reports. Aprea Therapeutics had a negative net margin of 1,645.01% and a negative return on equity of 78.90%.

Aprea Therapeutics Stock Down 4.5%

Shares of NASDAQ APRE traded down $0.06 during midday trading on Wednesday, hitting $1.26. The company had a trading volume of 3,386 shares, compared to its average volume of 47,775. The business has a 50-day simple moving average of $1.46 and a two-hundred day simple moving average of $1.63. Aprea Therapeutics has a twelve month low of $1.19 and a twelve month high of $5.00. The firm has a market capitalization of $7.35 million, a price-to-earnings ratio of -0.54 and a beta of 1.30.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $15.50.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.